Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

BioSketch

442 views

Published on

  • Be the first to comment

  • Be the first to like this

BioSketch

  1. 1. Principal Investigator/Program Director (Last, First, Middle): BIOGRAPHICAL SKETCH Provide the following information for the key personnel and other significant contributors in the order listed on Form Page 2. Follow this format for each person. DO NOT EXCEED FOUR PAGES. NAME POSITION TITLE Edwin Liu Assistant Professor, Pediatrics eRA COMMONS USER NAME liu.edwin EDUCATION/TRAINING (Begin with baccalaureate or other initial professional education, such as nursing, and include postdoctoral training.) DEGREE INSTITUTION AND LOCATION YEAR(s) FIELD OF STUDY (if applicable) Boston University BA 1989-1992 Medical Sciences Boston University School of Medicine MD 1992-1996 Medicine NOTE: The Biographical Sketch may not exceed four pages. Follow the formats and instructions on the attached sample.A. Positions and Honors.Positions and appointments1996-1997 Pediatric internship, St. Christopher’s Hospital for Children, Philadelphia, PA1997-1999 Pediatric residency, St. Christopher’s Hospital for Children, Philadelphia, PA1999-2003 Fellowship, The Children’s Hospital, Section of Pediatric Gastroenterology, Hepatology and Nutrition, Denver, CO2000-2003 Research Fellow, Barbara Davis Center for Childhood Diabetes, University of Colorado at Denver Health Sciences Center, Denver, CO2003-present Assistant Professor, Section of Pediatric Gastroenterology, Hepatology and Nutrition, The Childrens Hospital. Department of Pediatrics, University of Colorado School of Medicine.2003-present Research faculty, Barbara Davis Center for Childhood Diabetes, University of Colorado at Denver Health Sciences Center, Denver, COHonors and Awards2000 Outstanding Fellow Teaching Award, Gastroenterology, Hepatology and Nutrition, University of Colorado School of Medicine2001 Federation of Clinical Immunology Societies (FOCIS) conference travel award2002 Federation of Clinical Immunology Societies (FOCIS) conference travel award2003 Federation of Clinical Immunology Societies (FOCIS) conference travel award2004 Federation of Clinical Immunology Societies (FOCIS) conference travel award, Millennium Pharmaceuticals Young Investigator Award2006 Federation of Clinical Immunology Societies (FOCIS) conference travel award, by UCB PharmaceuticalsProfessional Societies1996-2001 American Academy of Pediatrics1999- American Gastroenterological Association1999- North American Society for Pediatric Gastroenterology, Hepatology, and Nutrition2001- Clinical Immunology Society2002- 2004 American Association of the Study of Liver Diseases2005- Society for Mucosal ImmunologyB. Selected Peer-Reviewed PublicationsOriginal peer-reviewed research publications:PHS 398/2590 (Rev. 09/04, Reissued 4/2006) Page Biographical Sketch Format Page
  2. 2. 1) Liu E, Hoffenberg EJ, Kaye RD, Sokol RJ. Endoscopic Dilation of an Ileocolonic Stricture in an Infant with Short GutSyndrome. Gastrointest Endosc. 2001 Oct;54(4):533-5.2) Kramer RE, Sokol RJ, Yerushalmi B, Liu E, MacKenzie T, Hoffenberg EJ, Narkewicz MR. Large-volume paracentesisin the management of ascites in children.J Pediatr Gastroenterol Nutr. 2001 Sep;33(3):245-9.3) Abiru N, Yu L, Miao D, Maniatis AK, Liu E, Moriyama H, Eisenbarth GS. Transient Insulin Autoantibody ExpressionIndependent of Development of Diabetes: Comparison of NOD and NOR Strains. J Autoimmun. 2001 Aug;17(1):1-6.4) Moriyama H, Wen L, Abiru N, Liu E, Yu L, Miao D, Gianani R, Wong FS, Eisenbarth GS.Induction and acceleration of insulitis/diabetes in mice with a viral mimic (polyinosinic-polycytidylic acid) and an insulinself-peptide.Proc Natl Acad Sci USA. 2002 Apr 16;99(8):5539-44.5) Liu E, Abiru N, Moriyama H, Miao D, Eisenbarth G. Induction of Insulin Autoantibodies and Protection from Diabeteswith Subcutaneous Insulin B:9-23 Peptide without Adjuvant. Annals of the New York Academy of Sciences. Immunologyof Diabetes: Autoimmune Mechanisms and the Prevention and Cure of Type 1 Diabetes. 958:224-227 (2002).6) Liu E, Moriyama H, Abiru N, Miao D, Yu L, Taylor RM, Finkelman FD and Eisenbarth GS. Anti-Peptide Autoantibodiesand Fatal Anaphylaxis with Insulin Self-Peptides B:9-23 and B:13-23. J. Clin. Invest. 2002 Oct;110(7):1021-7.7) Edwin Liu, MD, Fei Bao, MD, Katherine Barriga, MSPH, Dongmei Miao, MD, Liping Yu, MD, Henry A Erlich, PhD, JoelE Haas, MD, George S Eisenbarth, MD, PhD, Marian J Rewers, MD, PhD and Edward J Hoffenberg, MD. Fluctuatingtransglutaminase autoantibodies are related to histologic features of celiac disease. Clinical Gastroenterology andHepatology 2003;1:356–362.8) Hiroaki Moriyama, Norio Abiru , Johanna Paronen, Kamila Sikora, Edwin Liu, Dongmei Miao, Devasenan Davendra,Joshua Belike, Roberto Gianani, Ron G Gill and George S. Eisenbarth . Evidence for a primary islet autoantigen(preproinsulin 1 ) of the NOD mouse. Proc Natl Acad Sci U S A. 2003 Sep 2;100(18):10376-81.9) Edwin Liu, Hiroaki Moriyama, Johanna Paronen, Norio Abiru, Dongmei Miao, Liping Yu, Robert M. Taylor and GeorgeS. Eisenbarth. Nondepleting anti-CD4 monoclonal antibody prevents diabetes and blocks induction of insulinautoantibodies following insulin peptide B:9-23 immunization in the NOD mouse. Journal of Autoimmunity2003;21(3):213-219.10) Johanna Paronen, Hiroaki Moriyama, Norio Abiru, Kamila Sikora, Evie Melanitou, Sunanda Babu, Fei Bao, Edwin Liu,Dongmei Miao, George S. Eisenbarth. Establishing Insulin 1 and Insulin 2 knockout congenic strains on NOD geneticbackground. Ann N Y Acad Sci. 2003 Nov;1005:205-10.11) Melanitou E, Liu E, Miao D, Yu L, Glimcher LH, Eisenbarth GS. Absence of the T-bet gene coding for the Th1-related transcription factor does not affect diabetes-associated phenotypes in Balb/c mice. Ann N Y Acad Sci. 2003Nov;1005:187-91.12) Abiru N, Sun F, Kawasaki E, Yamasaki H, Oshima K, Nagayama Y, Mizuguchi H, Hayakawa T, Miao D, Liu E,Eisenbarth GS, Eguchi K. In vivo expression of B:9-23 peptide/I-A(g7) complex may abrogate the inhibition of diabetesinduced by RGD-fiber-mutant adenovirus in NOD mice. Ann N Y Acad Sci. 2003 Nov;1005:218-21.13) Johanna Paronen, Edwin Liu, Hiroaki Moriyama, Devasenan Devendra, Akane Ide, Taylor R, Liping Yu, DongmeiMiao, Evie Melanitou, George S Eisenbarth. Genetic differentiation of Poly-IC from B:9-23 peptide-induced experimentalautoimmune diabetes. J Autoimmun. 2004 Jun;22(4):307-13.14) Devendra D, Paronen J, Moriyama H, Miao D, Eisenbarth GS, Liu E. Differential immune response to B:9-23 insulin1 and insulin 2 peptides in animal models of type 1 diabetes. J Autoimmun. 2004 Aug;23(1):17-26.15) Liu E, Moriyama H, Abiru N, Paronen J, Devendra D, Finkelman FD and Eisenbarth GS. Preventing peptide-inducedanaphylaxis: addition of C-terminal amino acids to produce a neutral isoelectric point. J Allergy Clin Immunol. 2004Sep;114(3):607-13.PHS 398/2590 (Rev. 09/04, Reissued 4/2006) Page 2 Biographical Sketch Format Page
  3. 3. 16) Evie Melanitou, Devasenan Devendra, Edwin Liu, Dongmei Miao, and George S. Eisenbarth. Early and Quantal (byLitter) Expression of Insulin Autoantibodies in the Nonobese Diabetic Mice Predict Early Diabetes Onset. J Immunol.2004 Nov;173(11) 6603-10.17) Devendra D, Paronen J, Liu E, Moriyama H, Miao D & Eisenbarth GS. Comparative Study of Oral versusSubcutaneous B:9-23 insulin peptide in the Balb/c mouse as an experimental model to develop Autoimmune Diabetes.Ann N Y Acad Sci. 2004 Dec;1029:331-3.Paronen J, Liu E, Devendra D, Moriyama H, Miao D, Yu L & Eisenbarth GS. Differential immune induction withsubcutaneousversus oral administration of a diabetogenic insulin peptide in the NOD mouse. Ann N Y Acad Sci. 2004Dec;1029:328-30.19) Edwin Liu, Marcella Li, Fei Bao, Dongmei Miao, Marian J Rewers, George S Eisenbarth, Edward J Hoffenberg. ANeed for Quantitative Assessment of Transglutaminase Autoantibodies in Screening-Identified Children for CeliacDisease. J Pediatr. 2005 Apr;146(4):494-9.20) Edwin Liu, Marcella Li, Fei Bao, Dongmei Miao, Marian J Rewers, George S Eisenbarth, Edward J Hoffenberg. ANeed for Quantitative Assessment of Transglutaminase Autoantibodies in Screening-Identified Children for CeliacDisease. J Pediatr. 2005 Apr;146(4):494-9.19) Nakayama M, Abiru N, Moriyama H, Babaya N, Liu E, Miao D, Yu L, Wegmann DR, Hutton JC, Elliott JF, EisenbarthGS. Prime role for an insulin epitope in the development of type 1 diabetes in NOD mice. Nature. 2005 May12;435(7039):220-320) Devendra D, Jasinski J, Melanitou E, Nakayama M, Li M, Hensley B, Paronen J, Moriyama H, Miao D, EisenbarthGS, Liu E. Interferon-{alpha} as a Mediator of Polyinosinic:Polycytidylic Acid-Induced Type 1 Diabetes. Diabetes. 2005Sep;54(9):2549-56.21) Liu E, Mackenzie T, Dobyns EL, Parikh CR, Karrer FM, Narkewicz MR, Sokol RJ. Characterization of acute liverfailure and development of a continuous risk of death staging system in children. J Hepatol. 2006 Jan;44(1):134-141.22) Jean M. Jasinski, Liping Yu, Maki Nakayama, Marcella M. Li, Myra A. Lipes, George S. Eisenbarth and Edwin Liu.Transgenic Insulin (B:9-23) T Cell Receptor Mice Develop Autoimmune Diabetes Dependent upon RAG Genotype, H-2g7Homozygosity, and Insulin 2 Gene Knockout. Diabetes. 2006 Jul;55(7):1978-84.23) Tiberti C, Bonamico M, Dotta F, Verrienti A, Di Tola M, Liu E, Ferri M, Nenna R, Picarelli A, Eisenbarth GS.Evidenceof a selective epitope loss of anti-transglutaminase immunoreactivity in gluten-free diet celiac sera: a new tool todistinguish disease-specific immunoreactivities. Clin Immunol. 2006 Oct;121(1):40-6.24) Nakayama M, Babaya N, Miao D, Gianani R, Liu E, Elliott JF, Eisenbarth GS. Long-term prevention of diabetes andmarked suppression of insulin autoantibodies and insulitis in mice lacking native insulin B9-23 sequence. Ann N Y AcadSci. 2006 Oct;1079:122-9.25) Devendra D, Miao D, Nakayama M, Eisenbarth GS, Liu E. Pancreatic autoimmunity induction with insulin B:9-23peptide and viral mimics in the NZB mouse. Ann N Y Acad Sci. 2006 Oct;1079:135-7.26) Hoffenberg EH, Liu E. Celiac disease for the allergist: who and how to screen. Allergy Asthma Proc. 2007 Jan-Feb;28(1):20-4.27) Edwin Liu, Marcella Li, Lisa Emery, Iman Taki, Kathy Barriga, Claudio Tiberti, George S. Eisenbarth, Marian JRewers, Edward J. Hoffenberg. Natural history of antibodies to deamidated gliadin peptides and transglutaminase inearly childhood celiac disease. JPGN, in press.C. ACTIVE SUPPORT1) 1 K08 DK064605-01 (Liu) 7/1/03-6/30/08 75%NIH $119,750Career Development Award - Altering the pI of Peptide Vaccines to Avoid Anaphylaxis.PHS 398/2590 (Rev. 09/04, Reissued 4/2006) Page 3 Biographical Sketch Format Page
  4. 4. Modifying insulin peptides to prevent anaphylaxis, while maintaining immunogenicity for diabetes prevention. Peptidevaccines carry a potential risk of inducing anaphylaxis (i.e. insulin peptide B:9-23), which is influenced by the speed atwhich a peptide is absorbed into the systemic circulation in a sensitized animal. Modification of the native peptide by theaddition of 2 arginine amino acids to the C-terminus alters the pI from 5.4 to 7.0. This modification reduces peptidesolubility once injected subcutaneously, and results in delayed absorption and anaphylaxis prevention.2) Autoimmunity Prevention Centers pilot project award (PI Liu)2007-2008 $75,000A Shannon-entropy based bioinformatics method for autoantigen prediction in autoimmunity.Testing the hypothesis that for many autoimmune diseases, cell type-specific autoantibodies react to autoantigensexpressed with reasonable selectivity in the target cell, using a bioinformatics method to create a list of candidateautoantigens testing using serology.3) Autoimmunity Prevention Center U-01 pilot award (PI Ravetch) 2007-2008 $25,000Modulation of type 1 diabetes by IVIGStudy of asialyated IVIG as a protective reagent in type 1 diabetes.COMPLETED RESEARCH SUPPORT1) T32 AI07365 (Hayward/Gelfand) (PI) 7/1/01 – 6/30/03 80%NIH training grantStudy of insulin peptide as potential vaccine for immunotherapy of type 1 diabetes2) Children’s Hospital Research Institute’s Research Scholar Award (Liu) 2003 75%Altering the pI of Peptide Vaccines to Avoid anaphylaxis $20,000Modifying insulin peptides to prevent anaphylaxis, while maintaining immunogenicity for diabetes prevention. Peptidevaccines carry a potential risk of inducing anaphylaxis (i.e. insulin peptide B:9-23), which is influenced by the speed atwhich a peptide is absorbed into the systemic circulation in a sensitized animal. Modification of the native peptide by theaddition of 2 arginine amino acids to the C-terminus alters the pI from 5.4 to 7.0. This modification reduces peptidesolubility once injected subcutaneously, and results in delayed absorption and anaphylaxis prevention.3) GIDH Basic Research Award 2005-2006 $50,000Defining the potential role of costimulation by enterocytes in celiac disease.Role: PIInvestigation of potential costimulatory molecules in enterocytes of mice and humans as a possible mechanism of celiacdisease.4) 2006-2007 Liu (PI)DERC pilot and feasibility award 2006-2007 $50,000Pathways to anti-islet autoimmunity and diabetes through type 1 interferons.PHS 398/2590 (Rev. 09/04, Reissued 4/2006) Page 4 Biographical Sketch Format Page

×